陈丽,杨珏,邱剑飞,苑春茂,吴昌学,李艳梅,郝小江
CHEN Li,YANG Jue,QIU Jianfei,YUAN Chunmao,WU Changxue,LI Yanmei,HAO Xiaojiang

• 1:贵州中医药大学
• 2:贵州省中科院天然产物化学重点实验室
• 3:贵州医科大学

摘要(Abstract)：

目的:研究Isogarcinol对人红白血病细胞HEL的凋亡、增殖的影响及其作用机制。方法:采用不同浓度的Isogarcinol化合物处理HEL细胞,分别采用MTT测定细胞活力,Annexin V/PI双染流式细胞术检测细胞凋亡,细胞计数绘制细胞生长曲,Western blot和qRT-PCR法检测胞内信号通路相关基因在蛋白和基因水平的表达,利用SCID白血病小鼠模型体内评价该化合物的作用。结果:Isogarcinol抑制人红白血病细胞HEL的活性,IC505.4μmol/L可显著抑制人红白血病细胞HEL的增殖及诱导细胞凋亡; qRT-PCR结果显示促凋亡基因Bax的表达增加,而Caspase-3、Caspase-8的表达发生下调,抗凋亡基因Bcl-2、c-Myc的表达下调; Western blot结果显示Bad,Bax,Cleaved caspase-3,Cleaved caspase-8和Cleaved PARP的相对表达量呈浓度依赖性上调,而JAK2,PStat3、Bcl-2、Caspase3、Caspase-8、PARP、P-ERK 1/2和c-Myc的相对表达量呈浓度依赖性下调;小鼠体内实验表明Isogarcinol显著延长了小鼠的存活时间,并且增加了血红细胞比。结论:Isogarcinol诱导人红白血病细胞HEL细胞凋亡和抑制HEL细胞增殖,可能通过抑制JAK2/STAT3信号通路而实现的。
Objective:To study the effect and mechanism of Isogarcinol on apoptosis and proliferation of human erythroleukemia cell line HEL.Methods:MTT assay was used to measure the inhibition rate of different concentration of Isogarcinol on HEL cells.Apoptosis was detected by Annexin V/PI staining using flow cytometry.Cell growth curve was drawn based on cell counting data.Expressions of intracellular signal pathway-related proteins and genes were detected by Western blot and qRT-PCR.HEL tumor-bearing SCID mice were used to evaluate antitumor effect of this compound.Results:Isogarcinol significantly inhibited HEL cell viability and induced HEL cellular apoptosis,and its IC50 was 5.4 μmol/L.qRT-PCR results showed that the expression of proapoptotic gene Bax was increased,while the expression levels of Caspase-3 and Caspase-8 were downregulated.In addition,the expression levels of anti-apoptotic genes Bcl-2 and c-Myc were downregulated.Western blot analysis showed that the expression levels of Bad,Bax,Cleaved caspase-3,Cleaved caspase-8 and Cleaved PARP were upregulated in dose-dependent manner;while the expression levels of JAK2,P-Stat3,Bcl-2,Caspase3,Caspase-8,PARP,P-ERK 1/2 and c-Myc were down-regulated in dose-dependent manner.Moreover,Isogarcinol significantly prolonged the survival of HEL tumor-bearing mice and increased the hematocrit ratio.Conclusion:Isogarcinol induces apoptosis of HEL cells and inhibits HEL cell proliferation,which may be achieved by inhibiting JAK2/STAT3 signaling pathway.

关键词(KeyWords)： Isogarcinol;人红白血病细胞;细胞增殖;细胞凋亡;JAK2/STAT3信号通路
isogarcinol;human erythroleukemia cell line;cell proliferation;apoptosis;JAK2/STAT3 signaling pathway

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81700169);; 贵州省科技合作计划项目[黔科合LG字(2012)009]

作者(Author): 陈丽,杨珏,邱剑飞,苑春茂,吴昌学,李艳梅,郝小江
CHEN Li,YANG Jue,QIU Jianfei,YUAN Chunmao,WU Changxue,LI Yanmei,HAO Xiaojiang

DOI: 10.19367/j.cnki.1000-2707.2019.01.007

参考文献(References)：

• [1]贾秀红,尹宝慧,李建厂.黄芪注射液对U937细胞增殖与凋亡的影响及相关机制的探讨[J].中国当代儿科杂志,2013,15(12):1128-1133.
• [2]刘笑梦,曹娇玲,臧玉柱.人参皂苷对人白血病细胞凋亡的影响[J].中国当代儿科杂志,2012,14(10):792-795.
• [3]陈菲莉,柳约坚,李蓉蔚,等.雷公腾内酯与多柔比星诱导耐药白血病细胞凋亡协同作用及其机制的探讨[J].中华肿瘤防治杂志,2014,12(10):728-731.
• [4]KHWAJA A,BJORKHOLM M,GALE R E,et al.Acute myeloid leukaemia[J].Nature Reviews Disease Primers,1998,19(8):493-494.
• [5]COOMBS C C,TALLMAN M S,LEVINE R L.Molecular therapy for acute myeloid leukaemia[J].NATURE Reviews Clinical Oncology,2016,13(5):305.
• [6]LO-COCO F,CICCONI L,BRECCIA M.Current standard treatment of adult acute promyelocytic leukaemia[J].British Journal of Haematology,2016,172(6):841-854.
• [7]DOHNER H,WEISDORF D J,BLOOMFIELD C D.A-cute myeloid leukemia[J].Gan to Kagaku Ryoho Cancer&Chemotherapy,2001,28(9):1136-1152.
• [8]DELSAL G,LODA M,PAGANO M.Cell cycle and cancer:critical events at the G1 restriction point[J].Crit Rev Oncog,1996,7(1-2):127-142.
• [9]范翊民.多花山竹子中PPBS类成分的分离与新型Wnt信号通路激活剂莪术醇的结构优化[D].贵阳:贵州大学,2016.
• [10]LOWENBERG B,DOWNING J R,BURNETT A.Acute myeloid leukemia[J].N Engl J Med,1999,341(14):1051-1062.
• [11]SWIRSKY D M,BASTOS M D,PARISH S E,et al.Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients[J].British Journal of Haematology,2010,64(3):435-453.
• [12]BOLANOSMEADE J,GUO C,GOJO I,et al.A phase II study of timed sequential therapy of acute myelogenous leukemia(AML)for patients over the age of 60:two cycle timed sequential therapy with topotecan,ara-C and mitoxantrone in adults with poor-risk AML[J].Leuk Res,2004,28(6):571-577.
• [13]CASTAIGNE S,CHEVRET S,ARCHIMBAUD E,et al.Randomized comparison of double induction and timedsequential induction to a"3+7"induction in adults with AML:long-term analysis of the Acute Leukemia French Association(ALFA)9000 study[J].Blood,2004,104(8):2467-2474.
• [14]BOLANOS-MEADE J,KARP J E,GUO C,et al.Timed sequential therapy of acute myelogenous leukemia in adults:a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside,idarubicin and etoposide[J].Leuk Res,2003,27(4):313-321.
• [15]GRIMWADE D,WALKER H,OLIVER F,et al.The importance of diagnostic cytogenetics on outcome in AML:analysis of 1,612 patients entered into the MRCAML 10 trial.The Medical Research Council Adult and Children's Leukaemia Working Parties[J].Blood,1998,92(7):2322-2333.
• [16]PETTENATI M J,PATIL S R,WATSON M S,et al.Pretreatment cytogenetic abnormalities are predictive of induction success,cumulative incidence of relapse,and overall survival in adult patients with de novo acute myeloid leukemia:results from Cancer and Leukemia Group B(CALGB 8461)[J].Blood,2002,100(13):4325.
• [17]MARCUCCI G,MRóZEK K,RUPPERT A S,et al.Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival,and higher relapse rate in adult acute myeloid leukemia:results from cancer and leukemia group B study 8461[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2004,22(12):2410.
• [18]RAMPAL R,MASCARENHAS J.Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm[J].Current Opinion in Hematology,2014,21(2):65-71.
• [19]NETWORK C G A.Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia[J].New England Journal of Medicine,2013,369(1):2059-2074.
• [20]ZHANG S J,RAMPAL R,MANSHOURI T,et al.Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome[J].Blood,2012,119(19):4480-4485.
• [21]LEVINE R L.JAK-Mutant Myeloproliferative Neoplasms[J].Curr Top Microbiol Immunol,2012,355:119-133.
• [22]SHAN J,OYUNGEREL B,BAO W,et al.Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications[J].Journal of Clinical Medicine Research,2016,8(4):284-296.
• [23]AL-SAMHARI M M,Al-Rasheed NM,Al-Rejaie S,et al.Possible involve-ement of the JAK/STAT signaling pathway in N-acetylcysteine-mediated antidepressant-like effects[J].Exp Biol Med,2016,241(5):509-518.
• [24]PARDANANI A,LABORDE R R,LASHO T L,et al.Safety and efficacy of CYT387,a JAK1 and JAK2 inhibitor,in myelofibrosis[J].Leukemia,2013,27(6):1322-1327.
• [25]OKU S,TAKENAKA K,KURIYAMA T,et al.JAK2V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation[J].Br J Haematol,2010,150(3):334-344.

文章评论(Comment)：